This article is more than 5 years old. Information may no longer be current.

Novartis reports 3% decrease in Alcon net sales in first quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Novartis reported Alcon net sales of $2.56 billion in the first quarter of 2015, a 3% decrease from $2.64 billion in the first quarter of 2014, according to a press release.

The Surgical franchise was driven by sales of the Centurion phacoemulsification cataract platform and disposables and continued growth of U.S. LenSx femtosecond cataract procedures, the release said.

IOL sales were flat, and Ophthalmic Pharmaceuticals sales were led by double-digit growth of Systane and fixed-dose glaucoma combination products.

Alcon operating income decreased 7% to $353 million in the first quarter from $380 million a year ago.

Novartis net sales decreased 7%. The company reported net sales of $11.9 billion in the first quarter of 2015 compared with $12.8 billion in the first quarter of 2014. Operating income decreased 1% to $2.79 billion from $2.82 billion.